The pathophysiology of sepsis has been studied intensively in recent years and a variety of opportunities for therapeutic intervention have been identified. A number of biological products including endotoxin antibodies, cytokine inhibitors and receptor antagonists have been evaluated after the failure of pharmacological doses of steroids to influence survival in septic shock. Despite a number of large, international multi-centre studies, the therapeutic promise of these various interventions remains unfulfilled. These trials have largely been conducted in intensive care units in a heterogeneous population of patients with various entry criteria and end-points of response. While the clinical trial must remain the standard for assessing safety and efficacy of new interventions there are opportunities to improve on the design, execution and analysis of these studies. Factors such as the appropriateness of antibiotic therapy, the adequacy of medical and surgical management, and the issue of withdrawal or withholding of life support are discussed in relation to these studies. Furthermore the role of an independent scientific extramural review committee is stressed, particularly in relation to the impact of confounding events of an unforeseen nature. The potential for improving the quality of the analyses of clinical trials of sepsis is illustrated by a recently completed study of the efficacy of a murine monoclonal antibody to human tumour necrosis factor-. 
Introduction
Serious sepsis is a major medical problem. Studies from the USA and Europe attest to its importance and possibly increasing incidence. 1 Annually, an estimated 400,000-600,000 persons develop sepsis in the USA 2 and, of these, approximately 35% die. 3 Although surgery, transplantation, cytotoxic chemotherapy, immunomodulation and other advances in the management of disease increase longevity, these techniques are often complicated by sepsis. Pre-existing disease of the heart, lungs, kidneys, liver and other organs clearly predisposes to infection and sepsis.
It is also clear that current management strategies for dealing with serious sepsis have intrinsic limitations. Despite the plethora of available antibiotics, the mortality rate for Gram-negative bacteraemia complicated by shock ranges from 50% to 80%, [3] [4] [5] [6] while the increasing problem of drug resistance is further threatening our ability to deal effectively with this infection. The economic burden of serious sepsis is enormous but poorly defined.
The past decade has witnessed impressive advances in our knowledge of the pathophysiology of sepsis. 7 The role of microbial products such as endotoxin and peptidoglycan have been extensively investigated. Likewise, the host response to sepsis at the cellular and molecular level is better understood. Clarification of host cytokine expression, interaction and regulation has rapidly led to opportunities for novel therapeutic intervention. 8 These and other investigational approaches are summarized in Table I . Some will be discussed further in relation to the problems and pitfalls that have arisen when these interventions have been studied in clinical trials.
In parallel with advances in knowledge concerning the basic science of sepsis has been the recognition that clinical definitions of disease expression and severity assessment are essential for an accurate and reproducible evaluation of host response to sepsis. The standardization of terms such as sepsis, sepsis syndrome, septic shock and refractory septic shock has been a significant advance and has been complemented by the introduction of such terms as the 'systemic inflammatory response' and 'multiple organ dysfunction syndrome'. 9 Likewise severity and chronic health indices such as the acute physiology and chronic health evaluation (APACHE) scoring systems 10, 11 have been widely adopted as indicators of severity and prognosis and have become an accepted part of intensive care management and the conduct of clinical trials in the septic patient. 9, 12 Clinical trials are widely accepted as the most effective method of evaluating the efficacy of medical management, including the testing of therapeutic interventions. However, they are difficult to perform, time-consuming and costly. Guidance on the design, execution and statistical analysis of trials of sepsis was not included in the guidelines for the evaluation of anti-infective drug products published by the Infectious Diseases Society of America (IDSA) in conjunction with the Food and Drug Administration 13 while Wenzel et al. 14 on behalf of the IDSA provided a helpful commentary on recent antiendotoxin studies but did not provide specific guidance on the design of future studies. 15 The consensus Conference of the American College of Physicians and Society of Critical Care Medicine has offered general points for guidance. 9 The history of therapeutic studies in sepsis has been one of unfulfilled expectations and conflicting results. 16 It is therefore appropriate to review some of the issues that might explain this state of affairs and to provide guidance on future studies since the clinical trial is likely to remain the final arbiter of the efficacy and safety of future interventions in the management of sepsis.
Lessons from former trials
Over the past two decades several biological therapies for the management of sepsis have been proposed. These have included various monoclonal antibodies, cytokines, cytokine receptors and their antagonists. 17 However, despite there usually being sound scientific reasons for their evaluation in humans, based on supporting experimental evidence in animal models suggesting potential clinical benefit, many of these agents have failed to be developed further following the results of clinical trial. Several remain under investigation but none is in clinical use.
Corticosteroids
The importance of the prospective, randomized, doubleblind study in the evaluation of new therapies for treating sepsis is illustrated by the historical issue concerning whether or not corticosteroids favourably influence the outcome of septic shock. Early studies were supportive of their role 18 and agents such as dexamethasone became extensively used in medical practice until several well designed prospective studies demonstrated a clear lack of benefit. [19] [20] [21] It is interesting to note that, despite this lack of support for the use of steroids, their use continued to be studied, the most recent study being an evaluation of their use in sepsis of childhood. 22 Here again the results failed to give support for their use. This series of trials was an omen for the frustrations that have accompanied the clinical evaluation of a variety of therapeutic interventions in the management of the septic patient.
Endotoxin antibodies
More recently the management of sepsis has focused on the potential for biological interventions, including monoclonal antibodies to endotoxin, [23] [24] [25] interleukin-1 (IL-1) receptor antagonists 26 and anti-tumour necrosis factor (TNF) antibodies. 27, 28 The clinical trials have all adopted the prospective multi-centre double-blind model and have usually chosen, as the primary end-point for efficacy, an intent-to-treat analysis of the reduction in 28 or 30 day allcause mortality. Secondary end-points have included time to reversal of shock and the reversal of organ systems failure. However, a large number of other analyses have been performed in the hope of demonstrating therapeutic benefit in sub-populations of patients, such as those with microbiologically documented bacteraemia or sepsis, with or without shock. By way of example, it is interesting to compare the studies of two anti-endotoxin antibodies, a mouse-derived (E5) and a human (HA-1A) monoclonal antibody to core endotoxins. 23, 24 Both agents were claimed to have demonstrated benefit in clinical trial but in different subpopulations of recipients; those with Gram-negative sepsis without refractory shock in the case of E5 and those with Gram-negative bacteraemia and shock for HA-1A. Table  II summarizes the key differences in design and analysis between these two studies. In a thoughtful commentary, Warren et al. 29 pointed out some of the design weaknesses and flaws in the analysis of the HA-1A study. These included a 'centre effect' with a benefit in patients with shock demonstrated only from centres with a high mortality rate. Other factors possibly biasing the outcome included the effect of inadequate or unknown antibiotic treatment, the known non-linear relationship between the APACHE II score and the risk of hospital death, 10, 30 and the problems in predicting mortality in post-operative surgical patients and those with multiple organ failure. 31 Finally, the interval between diagnosis of sepsis and the infusion of HA-1A was not subject to efficacy analysis but has obvious clinical relevance.
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A subsequent study of HA-1A (the CHESS study) 32 focused on the reduction in mortality in patients with Gram-negative bacteraemia and in shock. The authors claimed that the first HA-1A study 23 was an explanatory trial conducted in specialist centres with the objective of deciding whether or not benefit could be expected from the intervention. The second study differed in design and was claimed to be a pragmatic or management trial with the intention of assessing efficacy and safety under clinical circumstances resembling as closely as possible those actually or usually encountered in clinical practice. This second study used death within 14 days to assess efficacy. There was no provision for enrolling patients with organ failure and the design did not permit the collection of data regarding the severity of illness. Furthermore, many centres contributed very few patients, and this could have entered a further bias, while centres with a known higher mortality rate recruited more patients to the HA-1A arm. The CHESS study was stopped prematurely as a result of an interim analysis which called for discontinuation of the trial should deaths in the HA-1A arm exceed those in the placebo arm by (an arguably too stringent) P value of 0.1 (one-tailed test).
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Heterogeneity of test population
While progress has been made with regard to harmonization of the definitions of sepsis, there has been considerable heterogeneity within the test populations. For example, the mortality risk associated with urosepsis is much lower than that of intra-abdominal sepsis or that arising from the respiratory tract. 33, 34 It is also important to recognize the possible biases arising from international variation in medical practice. Relevant to this is the fact that there are far fewer general and specialist intensive care beds in the UK than in the rest of Europe and, more particularly, the USA. As a result, patients admitted to intensive care beds in the UK are often sicker, have higher APACHE II scores and in turn run the risk of a higher mortality rate. 35 The impact on international studies of sepsis should make adjustments for such variations in case-mix within different recruiting centres if bias is to be avoided. Single-centre studies have obvious advantages with regard to eliminating bias but few would be able to recruit sufficient patients within a reasonable length of time. Prolonged trials of themselves can present a bias in as far as 'investigator fatigue' can develop while, with the passage of time, advances in medical management may alter and influence patient care.
Withdrawal of life support
Another issue in trials of sepsis has been the recognition of centre variation in the withdrawal of life-sustaining therapies; this can lead to differences in the exact cause of death among recruited patients. 36, 37 This is quite distinct from issues such as inadequate medical or surgical management, inappropriate antimicrobial chemotherapy and the development of fatal complications or secondary diagnoses unrelated to the primary condition prompting trial entry. These factors can all adversely affect patient morbidity and mortality and in turn bias the outcome of the study. The issue of withdrawal of life-sustaining therapies is gaining momentum with pressure being exerted from political and patient lobbying organizations. Medical attitudes vary widely and reflect the conflict between the 'must do everything' attitude and the risk this might engender in relation to the quality of life among survivors, and the need to respect the wishes of patients and their next-of-kin in deciding the intensity and duration of life-sustaining therapies.
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Future directions
Antibiotic regimens
How can clinical trials of the management of serious sepsis be improved? It is clearly important that emphasis should be placed on ensuring that all strategies currently confirmed as effective are adopted. 39 These include optimal medical and surgical management, an accurate definition of the microbial basis for the sepsis syndrome and optimal antibiotic use supported by reliable laboratory data. With regard to antibiotic management there has been little emphasis on standardization of regimens adopted in sepsis trials. The assumption has been that many regimens will show comparable efficacy, and greater reliance has been placed on an assessment of appropriateness of use. However, it is known that the release of endotoxin from Gram-negative bacteria following antibiotic exposure differs. 40 For example, carbapenems such as imipenem cause less endotoxin release than some third-generation cephalosporins. 41 While the clinical relevance of these invitro observations remains uncertain it would appear prudent to limit the potential for bias through greater efforts at standardization of antibiotic management.
Monitoring biological response
Clinical trials of sepsis have to date made use of clinical end-points. This arguably has the advantage of defining clinical utility. However, the interventions tested have differed with regard to their presumed action on the pathophysiology of sepsis. 42 The ability to measure a specific pharmacodynamic effect of an intervention on a particular or surrogate target would appear advantageous. 43 For example, the measurement of a reduction in circulating endotoxin in anti-endotoxin studies, 44 or the demonstration of a reduction in TNF, IL-1, IL-6 or an increase in IL-10 in cytokine inhibition or stimulation studies have obvious theoretical attractions. However, it is recognized that there are limitations to this approach even though it has been adopted in some studies. 45, 46 At present the facility to provide these measurements is not routinely available outside the research environment. It also remains uncertain whether such measurements are truly predictive of changes occurring at the cellular level in the various clinical settings in which sepsis occurs. 47 Furthermore, the relationship between the kinetics of cytokine release and clinical response in sepsis remains unclear. 45 If biological interventions are to be applied to the management of sepsis it is important that greater efforts are made to develop a broad range of rapid and reliable diagnostic tests that allow early definition of host markers of impending or established sepsis and, ideally, also allow prompt detection of specific microbial products. This approach theoretically should permit greater precision in the selection of patients likely to benefit from these interventions.
End-points
As stated earlier, the clinical trial is fundamental to the assessment of new therapeutic interventions in humans. It is important in their future design that knowledge gained from earlier studies be taken into account. A particular issue is that of standardization of end-points for assessing efficacy and safety. 9 Some of the analyses that should be considered when designing these studies are: 28-, 14-or 3-day mortality; shock reversal; time to shock reversal; occurrence of secondary shock; number of organ/systems failure; time to onset of additional/secondary organ failure; reversal of organ failure(s); comparison of APACHE scores with baseline; mortality by APACHE score; duration of stay in ICU post-infusion; duration of hospital stay; serious or life-threatening adverse events; other intercurrent events. Mortality reduction has been the most widely adopted criterion for response in studies to date. However, it can be argued that changes in morbidities should be used or, if death is to remain an end-point, mortality at 3 days might be a better test of performance than death at 28 days, and more accurately reflect the immunopharmacology of the intervention. 48 The arguments favouring assessment of a reduction in morbidity rather than in mortality raise some concerns. Many of the agents tested or under evaluation possess antiinflammatory characteristics. The inflammatory response is clearly an important host response to infection and other stress stimuli and the effects of blockade may have harmful as well potentially beneficial effects. 2 7 Hence in the absence of a complete knowledge of the spectrum of activity of these agents, absolute reliance on morbidity reduction may of itself fail to detect any possible harmful effects from such interventions. Furthermore, while it is reasonable to consider that anti-inflammatory agents might influence early mortality as well as measurable morbidities associated with the inflammatory process, there is evidence that the risk of mortality due to sepsis persists for at least a month regardless of the underlying disease.
For these reasons 28 or 30 day mortality should remain the primary end-point for efficacy assessment rather than earlier assessment at 3 or 14 days. 9 A further reason for choosing mortality as the end-point is that future novel adjunctive agents would be difficult to evaluate if a favourable effect on morbidity alone were to be a criterion of efficacy. Placebo-controlled studies would become almost impossible to perform even though the impact on mortality of an agent affecting morbidity remained uncertain. Since it is likely that adjunctive therapies will eventually be shown to work best in combination, the ability to demonstrate an impact on multiple morbidities rather than mortality might well fail to detect the possible harmful effects of such combinations.
Other clinical models
It is clear that the testing of novel interventions in heterogeneous populations of patients cared for in different centres and in different medical cultures is likely to continue. One approach, therefore, would be to select a more homogeneous clinical model of infection. However, few exist. The endotoxin antibody HA-1A remains under clinical evaluation in the management of meningococcal sepsis. This is a well characterized clinical model usually occurring in previously fit young persons and with a high mortality. Few of the confounding issues of pre-existing disease or major variations in antibiotic management are likely to complicate such studies. The opportunity to sample serially for changes in circulating cytokines and endotoxin concentrations in this model could provide supporting data which would assist in the selection of appropriate patients should the intervention be shown to be beneficial.
Scientific extramural review committees
Another strategy that has been adopted in recent trials of sepsis has been the use of an independent clinical evaluation committee (CEC) to improve the quality and validity of the data from large multi-centre studies. 33 The exact workings of such committees have not been described in detail until recently. The author contributed to a scientific extramural review committee (SERC) 49 which independently monitored a prospective international three-arm, double-blind, placebo-controlled randomized study of the efficacy and safety of the administration of either highdose (15 mg/kg) or low-dose (3 mg/kg) murine monoclonal antibody to human TNF-to patients with sepsis (INTER-SEPT study). 28 None of the four members of SERC was an investigator in the trial. Their expertise covered the disciplines of critical care medicine, general internal medicine, medical microbiology and infectious diseases. Each case report form was individually examined to ensure eligibility by protocol for trial entry and that the definitions of shock and organ system failure were met.
Of importance were the SERC's assessment of the medical and surgical management, appropriateness of antibiotic treatment, and the reasons for withdrawal or withholding life-sustaining therapy and, in particular, its role in defining and analysing other unforeseen confounding events. The latter were defined as underlying or unforeseen conditions which might seriously interfere with the potential for the therapeutic agent to exercise its full effects. The confounding events recorded during the course of this trial include: 28,49 (i) inappropriate antimicrobial therapy: inappropriate empirical therapy, inappropriate targeted therapy, delayed therapy, therapy of insufficient duration or insufficient dosage; (ii) inadequate medical or surgical management; (iii) underlying or unforeseen conditions: pre-enrolment undiagnosed fatal condition, major haemorrhage, post-enrolment fatal condition unrelated to sepsis; (iv) therapy withheld and/or withdrawn before outcome was clear. This list includes those events ascribed to patients who, subsequent to trial entry, were designated 'do not resuscitate' for various medical reasons, and in whom, as a result, therapy was withheld and/or withdrawn before the outcome was clear.
The SERC review was carried out without knowledge of the randomization. At its conclusion two patient populations were available for analysis: those valid for safety and efficacy according to protocol and a second, identified as the 'SERC valid' group, which satisfied the same inclusion and exclusion criteria but in addition excluded patients with confounding events.
A total of 553 patients received anti-TNF or placebo during the INTERSEPT study of whom 77 (14%) were invalid for the protocol. A further 60 (11%) patients were considered to have confounding events by the SERC. When the intent-to-treat standard survival analysis of the INTERSEPT study was compared with that of the 'SERC valid' group, more pronounced advantages over placebo were observed in the 'SERC valid' populations treated with low dose (3 mg/kg) anti-TNF for all those studied as well as for those with shock. However, none of these differences achieved statistical significance, possibly owing to there being insufficient patients in the 'SERC valid' group to give the analysis sufficient power. 49 Recruitment to the 15 mg/kg arm was stopped following an interim analysis of the companion NORASEPT study which indicated that those treated with this higher dose appeared to have an excess of mortality compared with the placebo group. 27 Likewise there appeared to be no benefit in the patients not in shock so that recruitment to this arm of the study was abandoned.
28 Table III demonstrates these survival differences compared with placebo for the intentto-treat groups and for patients in shock treated with 3 mg/kg anti-TNF-analysed for both the 'by protocol' and 'SERC valid' groups.
The value of this SERC assessment ensured not only strict adherence to the protocol but also provided an independent professional assessment of various critical aspects of the patient population such as the nature of the underlying disease, the primary site of infection, the quality of the microbiological assessment, the appropriateness of the antibiotic management, the overall standard of care and the 'do not resuscitate' issues. 36 Thus a more refined population of subjects was described in whom the therapeutic potential of the study drug could be more fairly assessed by eliminating biases which are inherent in any simple randomization of patients such as those suffering from the sepsis syndrome.
Conclusion
Clinical trials must remain the gold standard for assessing efficacy and safety of new therapies for sepsis. Such trials demand energy, enthusiasm, and organizational and statistical skills in addition to a sound hypothesis, based on preclinical experimental data, which should be consistent with our current understanding of the pathophysiology of sepsis. Clinical trials are important in protecting patients from possible harm and society from possible commercial exploitation. Likewise they provide the means for ensuring progress in medicine is scientifically sound and evidenced based.
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The prospective double-blind, multi-centre phase III study is expensive to perform and requires careful design. Exploratory phase II studies are considered essential for defining the potential impact of any new anti-inflammatory agent on the sepsis syndrome, in order that subsequent phase III studies are appropriately designed not only to identify differences in mortality but also to be of sufficient power to identify sub-populations who can be well characterized at final entry, thus ensuring greater external validity and clinical relevance. They should also be large enough to accommodate exclusions based on confounding events in addition to the standard range of exclusion criteria. Exploratory phase II trials should also include dose ranging studies and ideally monitor host inflammatory markers to assist in the interpretation of any observed beneficial or harmful effects. 
